http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100646576-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01B63-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01B59-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 |
| filingDate | 2005-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100646576-B1 |
| titleOfInvention | Combined Pellets Containing HMG-CO Reductase Inhibitor and Enteric-Coated Aspirin for Prevention of Atherosclerosis in Patients with Hyperlipidemia |
| abstract | The present invention relates to a composite pellet comprising aspirin and HMG-CoA reductase inhibitors, and more particularly, to a composite pellet coated with an enteric coating on the outside of the main layer containing aspirin and an HMG-CoA reductase. The composite pellet according to the present invention comprises a main layer coated with 25 to 35% by weight of aspirin in 40 to 60% by weight of inert sugar particles; An enteric base layer coated with 10 to 15 wt% of the enteric base on the outside of the main layer; and an outer layer coated with 2.5 to 15 wt% of the HMG-CoA reductase inhibitor on the outside of the enteric base layer, wherein the HMG The -CoA reductase inhibitor is characterized in that it is one drug selected from the group consisting of simvastatin, atorvastatin calcium and roschvastatin calcium.n n n n Pellets, nuclear tablets, aspirin, HMG-CoA reductase inhibitors, hyperlipidemia |
| priorityDate | 2005-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.